AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12065207 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose candesartan (16 mg)
Number of subjects: 116
Study 12065207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose candesartan (8 mg)
Number of subjects: 116
Study 12065207 — intervention group
Group type: COMPARATOR
Intervention: Standardised medication
Number of subjects: 116
Study 10049410 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral endoscopy
Number of subjects: 170
Study 10049410 — intervention group
Group type: COMPARATOR
Intervention: Transnasal endoscopy
Number of subjects: 170
Study 10049410 — intervention group
Group type: COMPARATOR
Intervention: Videoendoscope (larger diameter)
Number of subjects: 170
Study 10049410 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic endoscope (smaller diameter)
Number of subjects: 170
Study 10049410 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope insertion by oral route
Number of subjects: 170
Study 10049410 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient tolerance
Number of subjects: 170
Study 8786163 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus preparation for 10 days
Number of subjects: 9
Study 31036091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively‐Based Compassion Training (CBCT)
Number of subjects: 40
Study 31036091 — intervention group
Group type: COMPARATOR
Intervention: Cancer health education (CHE)
Number of subjects: 40
Study 28276566 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 8240
Study 28276566 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 8240
Study 28276566 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (low risk)
Number of subjects: 8240
Study 28276566 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (high risk)
Number of subjects: 8240
Study 28276566 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (high risk)
Number of subjects: 8240
Study 28276566 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (high risk)
Number of subjects: 8240
Study 25964594 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy (3DCRT) with hormonal therapy (HT) administered in 92% of patients
Number of subjects: 97
Study 23663336 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (n = 23)
Number of subjects: 35
Study 23663336 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 12)
Number of subjects: 35
Study 21900148 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet (LGI)
Number of subjects: 99
Study 21900148 — intervention group
Group type: COMPARATOR
Intervention: High-fiber moderate-GI diet (HF)
Number of subjects: 99
Study 18569470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 57
Study 18569470 — intervention group
Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 (Prostin)
Number of subjects: 57
Study 16059533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing with sterile gauze (EG 1)
Number of subjects: 68
Study 16059533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing with sterile transparent film (EG 2)
Number of subjects: 68
Study 16059533 — intervention group
Group type: COMPARATOR
Intervention: Hypoallergenic adhesive tape (CG)
Number of subjects: 68
Study 12066725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/nitrous oxide anaesthesia
Number of subjects: 20
Study 12066725 — intervention group
Group type: COMPARATOR
Intervention: Propofol i.v. anaesthesia
Number of subjects: 20
Study 10581657 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 4 mg
Number of subjects: 301
Study 10581657 — intervention group
Group type: COMPARATOR
Intervention: FP 1 mg
Number of subjects: 301
Study 10581657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 8694380 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane induction/halothane maintenance (group H/H)
Number of subjects: 80
Study 8694380 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance (group P/P)
Number of subjects: 80
Study 8694380 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane induction/propofol maintenance (group H/P)
Number of subjects: 80
Study 8694380 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction/halothane maintenance (group P/H)
Number of subjects: 80
Study 8694380 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (nitrous oxide and oxygen administered)
Number of subjects: 80
Study 8694380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomiting within the first 6 h
Number of subjects: 80
Study 1812903 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine solution (1 mL) irrigation
Number of subjects: 12
Study 1812903 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline or no irrigation (control)
Number of subjects: 12
Study 6682323 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg carteolol p.o.
Number of subjects: 28
Study 6682323 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 2, 5 or 25 mg carteolol
Number of subjects: 28
Study 6682323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg carteolol
Number of subjects: 28
Study 6682323 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 to 25 mg carteolol
Number of subjects: 28
Study 6682323 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol
Number of subjects: 28
Study 30872010 — intervention group
Group type: EXPERIMENTAL
Intervention: MARQUE intervention
Number of subjects: 404
Study 30872010 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 404
Study 29059510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE) at 80% V˙O2 R
Number of subjects: 10
Study 29059510 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MIE) at 50% V˙O2 R
Number of subjects: 10
Study 29059510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Exercise (LIE) at 35% V˙O2 R
Number of subjects: 10
Study 29059510 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 10
Study 29059510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Exercise (LIE)
Number of subjects: 10
Study 26907584 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth diary and symptom-tracking tool combined with person-centered care (PCC)
Number of subjects: 199
Study 26907584 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC without eHealth tool
Number of subjects: 199
Study 26907584 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 199
Study 24923300 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Package of CV risk assessment, patient education, initiation and titration of antihypertensive medications, behavioral counseling on lifestyle behaviors, and medication adherence every three months for 12 months.
Number of subjects: 640
Study 22172088 — intervention group
Group type: EXPERIMENTAL
Intervention: New logical memory stories
Number of subjects: 240
Study 22172088 — intervention group
Group type: COMPARATOR
Intervention: Traditional Wechsler Memory Scales stories
Number of subjects: 240
Study 19653548 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate linear regression models
Number of subjects: 0
Study 19653548 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in response or exit score as a function of baseline response
Number of subjects: 0
Study 19653548 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including baseline response as covariate
Number of subjects: 0
Study 18760122 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery strategy (surgical procedure performed within 48 hours of randomization)
Number of subjects: 216
Study 18760122 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art therapeutic strategy (advised by international societies in their guidelines)
Number of subjects: 216
Study 18760122 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up substudy
Number of subjects: 216
Study 15703368 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxymorphone ER (3 x 20 mg q12h) + naltrexone (50 mg q24h)
Number of subjects: 0
Study 15703368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oxymorphone ER (10-20 mg q12h)
Number of subjects: 0
Study 15703368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (2 x 300 mg q24h)
Number of subjects: 0
Study 15703368 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg q24h)
Number of subjects: 0
Study 15703368 — intervention group
Group type: COMPARATOR
Intervention: CYP probes alone (controls)
Number of subjects: 0
Study 12369078 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for acute myocardial infarction
Number of subjects: 0
Study 12369078 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10064246 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/d for 12 months)
Number of subjects: 108
Study 10064246 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (200 mg/d for 12 months)
Number of subjects: 108
Study 8613283 — intervention group
Group type: EXPERIMENTAL
Intervention: UV lamp method for assessing compliance
Number of subjects: 0
Study 8613283 — intervention group
Group type: COMPARATOR
Intervention: Torch light method for assessing compliance
Number of subjects: 0
Study 8613283 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of UV lamp and torch light methods
Number of subjects: 0
Study 2188312 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating air (AA) mattress overlay
Number of subjects: 187
Study 2188312 — intervention group
Group type: COMPARATOR
Intervention: Silicore (S) mattress overlay
Number of subjects: 187
Study 2188312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both overlays (AA and S)
Number of subjects: 187
Study 6105519 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 20 mg daily
Number of subjects: 101
Study 6105519 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 100 mg daily
Number of subjects: 101
Study 6105519 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 20 mg and azathioprine 50 mg daily
Number of subjects: 101
Study 6105519 — intervention group
Group type: COMPARATOR
Intervention: B vitamins 2 tablets daily
Number of subjects: 101
Study 30997140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual red imaging (DRI)
Number of subjects: 0
Study 30997140 — intervention group
Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 0
Study 29691625 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 8
Study 27598452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulley suture technique
Number of subjects: 21
Study 27598452 — intervention group
Group type: COMPARATOR
Intervention: Bilayered closure
Number of subjects: 21
Study 24768658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Cardiovascular Health Training Classroom (CHTC)
Number of subjects: 150
Study 24768658 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No specific intervention mentioned
Number of subjects: 150
Study 21987667 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation system (MECC)
Number of subjects: 40
Study 21987667 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB
Number of subjects: 40
Study 20181334 — intervention group
Group type: EXPERIMENTAL
Intervention: Written educational material provided to the case group
Number of subjects: 140
Study 20181334 — intervention group
Group type: COMPARATOR
Intervention: Brief information about pre-endoscopy preparation (control group)
Number of subjects: 140
Study 17828096 — intervention group
Group type: EXPERIMENTAL
Intervention: Perftorane
Number of subjects: 76
Study 15386757 — intervention group
Group type: EXPERIMENTAL
Intervention: 19‐min video developed for this study
Number of subjects: 79
Study 15386757 — intervention group
Group type: COMPARATOR
Intervention: Written pamphlet control condition
Number of subjects: 79
Study 12091194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with lithium and adjunctive psychotherapy specific to bipolar disorder
Number of subjects: 0
Study 12091194 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy with lithium and nonspecific intensive clinical management
Number of subjects: 0
Study 10484310 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preparatory program
Number of subjects: 0
Study 10484310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preparatory program)
Number of subjects: 0
Study 8942490 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose triptorelin for 8 weeks followed by reduced-dose triptorelin (100, 20, or 5 micrograms) until week 26
Number of subjects: 27
Study 8942490 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose triptorelin (100, 20, or 5 micrograms)
Number of subjects: 27
Study 8942490 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose triptorelin
Number of subjects: 27
Study 8942490 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose triptorelin
Number of subjects: 27
Study 1959366 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic dosing of aminoglycosides
Number of subjects: 95
Study 1959366 — intervention group
Group type: COMPARATOR
Intervention: Traditional physician-directed techniques
Number of subjects: 95
Study 6181452 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session argon laser photocoagulation
Number of subjects: 0
Study 6181452 — intervention group
Group type: COMPARATOR
Intervention: Multiple sessions of argon laser photocoagulation
Number of subjects: 0
Study 29482614 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+app
Number of subjects: 150
Study 29482614 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+app+alarms
Number of subjects: 150
Study 29482614 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 150
Study 26830676 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone simulation training (4 sessions over 6-8 months)
Number of subjects: 160
Study 26830676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 26830676 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone simulation training
Number of subjects: 160
Study 25193506 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day ranitidine
Number of subjects: 75
Study 25193506 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day ranitidine
Number of subjects: 75
Study 25193506 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 75
Study 23583763 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and carvedilol (n = 45)
Number of subjects: 90
Study 23583763 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 45)
Number of subjects: 90
Study 20874458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) 200/10 μg
Number of subjects: 404
Study 20874458 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/S) 250/50 μg
Number of subjects: 404
Study 20874458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) 400/10 μg
Number of subjects: 404
Study 20874458 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/S) 500/50 μg
Number of subjects: 404
Study 20874458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F)
Number of subjects: 404
Study 20874458 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/S)
Number of subjects: 404
Study 20874458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MF/F and FP/S
Number of subjects: 404
Study 18688066 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose sirolimus-eluting stents (SES) (280 microg/cm2)
Number of subjects: 39
Study 18688066 — intervention group
Group type: COMPARATOR
Intervention: Single-dose sirolimus-eluting stents (SES) (140 microg/cm2)
Number of subjects: 39
Study 16377679 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 200
Study 16377679 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 200
Study 16377679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 14733381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet with a brief educational message and a 2-minute scripted overview
Number of subjects: 103
Study 14733381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 103
Study 10807457 — intervention group
Group type: COMPARATOR
Intervention: Troponin T
Number of subjects: 447
Study 10807457 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 447
Study 8813924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 10 mg
Number of subjects: 12
Study 8813924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 12
Study 8813924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 12
Study 8813924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 12
Study 8813924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1311660 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 17
Study 4082876 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol as a skin disinfectant
Number of subjects: 187
Study 4082876 — intervention group
Group type: COMPARATOR
Intervention: No skin disinfectant
Number of subjects: 187
Study 31325313 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided treatment
Number of subjects: 119
Study 31325313 — intervention group
Group type: COMPARATOR
Intervention: Standard care respiratory control
Number of subjects: 119
Study 29807859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet air sterilizer (UVAS)
Number of subjects: 1097
Study 26674372 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 30
Study 26674372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25775393 — intervention group
Group type: COMPARATOR
Intervention: Positive expression of CDC25B protein (48.5%)
Number of subjects: 66
Study 25775393 — intervention group
Group type: COMPARATOR
Intervention: Positive expression of PED/PEA‐15 protein (68.2%)
Number of subjects: 66
Study 25775393 — intervention group
Group type: COMPARATOR
Intervention: PED/PEA‐15 positive expression group
Number of subjects: 66
Study 23469602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidan Mixture (LM) combined with ganciclovir
Number of subjects: 240
Study 23469602 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir alone
Number of subjects: 240
Study 20210619 — intervention group
Group type: EXPERIMENTAL
Intervention: S1: Cold water immersion (2 degrees C) until T(re) reached 37.5 degrees C
Number of subjects: 24
Study 20210619 — intervention group
Group type: EXPERIMENTAL
Intervention: S2: Recovery in a temperate environment (30 degrees C, 30% relative humidity) for 60 minutes
Number of subjects: 24
Study 18586126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral training
Number of subjects: 106
Study 18586126 — intervention group
Group type: COMPARATOR
Intervention: Unilateral training
Number of subjects: 106
Study 15707912 — intervention group
Group type: EXPERIMENTAL
Intervention: True enactment of verbal material
Number of subjects: 0
Study 15707912 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 11817465 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence products (10%, 15%, 20%)
Number of subjects: 0
Study 11817465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nite White products (10%, 16%, 22%)
Number of subjects: 0
Study 11817465 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt products (10%, 15%, 22%)
Number of subjects: 0
Study 11817465 — intervention group
Group type: EXPERIMENTAL
Intervention: Trays with reservoirs (Opalescence)
Number of subjects: 0
Study 11817465 — intervention group
Group type: EXPERIMENTAL
Intervention: Trays without reservoirs
Number of subjects: 0
Study 9973007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin
Number of subjects: 12
Study 9973007 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg diltiazem‐CD
Number of subjects: 12
Study 9973007 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 12
Study 9973007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin + 240 mg diltiazem‐CD
Number of subjects: 12
Study 9973007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin + 50 mg atenolol
Number of subjects: 12
Study 9973007 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin + atenolol
Number of subjects: 12
Study 9973007 — intervention group
Group type: EXPERIMENTAL
Intervention: regimens including atenolol
Number of subjects: 12
Study 9973007 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin and digoxin + atenolol
Number of subjects: 12
Study 9973007 — intervention group
Group type: COMPARATOR
Intervention: all treatment groups
Number of subjects: 12
Study 7573259 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin
Number of subjects: 495
Study 7573259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 7573259 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin sensitivity test
Number of subjects: 495
Study 2183591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate
Number of subjects: 102
Study 2183591 — intervention group
Group type: COMPARATOR
Intervention: Golytely (standard polyethylene glycol-based lavage solution)
Number of subjects: 102
Study 77993 — intervention group
Group type: EXPERIMENTAL
Intervention: Local zinc sulphate application
Number of subjects: 10
Study 77993 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment application
Number of subjects: 10
Study 30801390 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-close Port-site Closure System
Number of subjects: 0